Praising Cardiff Oncology, Piper Sandler analyst Joseph Catanzaro upgraded the stock to an Overweight rating and bumped up the price target to $7 from $5. This change comes after a previous adjustment where the price target was decreased from $7 to $5. Various analysts have offered different price targets for Cardiff Oncology, averaging at $8.67 for the next year. Joseph Catanzaro had originally set the price target at $7 before the recent modification.
CRDF Stock Surges 52.79% on March 1, 2024: Investors Optimistic for Continued Growth
On March 1, 2024, CRDF stock showed strong performance, with the price of shares increasing by $0.93 since the market last closed, representing a significant 52.79% rise in value. CRDF is currently trading in the middle of its 52-week range and above its 200-day simple moving average, indicating a bullish trend in the longer term. The stock opened at $2.00 on March 1, reflecting investor optimism and setting a positive tone for the day. Investors will be closely watching to see if this positive momentum continues.
CRDF Stock Performance Analysis: Revenue Growth, Net Income Improvement, and EPS Decline
On March 1, 2024, CRDF stock experienced mixed performances based on its financial data. According to CNN Money, the company reported a total revenue of $386.00K for the past year, which is a 7.52% increase compared to the previous year. In the third quarter, CRDF generated $141.00K in total revenue, marking a significant 30.56% increase compared to the previous quarter.
However, the company’s net income showed a different trend. CRDF reported a net income of -$38.70M for the past year, indicating a 36.81% decrease compared to the previous year. In the third quarter, the company’s net income improved to -$9.73M, representing a 12.73% increase compared to the previous quarter.
Earnings per share (EPS) also showed a mixed performance for CRDF stock. The company reported an EPS of -$0.89 for the past year, which is a 22.44% decrease compared to the previous year. In the third quarter, the company’s EPS improved to -$0.22, marking a 12.74% increase compared to the previous quarter.
Overall, CRDF stock’s financial performance on March 1, 2024, reflected a combination of revenue growth and net income improvement, but with a decline in EPS compared to the previous year. Investors may want to closely monitor the company’s future financial reports to assess its long-term growth prospects and stock performance.
